Article

ATLAS lung cancer trial fails to show survival benefit

Author(s):

Despite touting one year ago that adding Tarceva (erlotinib) to Avastin (bevacizumab) after initial treatment with Avastin extended the time advanced non-small cell lung cancer patients lived without their disease getting worse, researchers have now found the combination did not help patients live longer. The follow-up data were released today at the annual meeting of the American Society of Clinical Oncology.CURE first reported on the trial, dubbed ATLAS, at last year's ASCO meeting, but at the time, overall survival data were still to come. In a poster presented at this year's meeting, investigators reported that although the drug combination delayed disease progression for 4.8 months compared with 3.7 months for Avastin alone, no significant difference was seen in how long patients survived (14.4 months for the combination versus 13.3 months for Avastin alone).Researchers said that based on this latest analysis, maintenance therapy with Avastin and Tarceva should not be a standard option for these patients.Read more about the latest options for treating non-small cell lung cancer in "Lung Overdue" from CURE's Spring 2010 issue.Melissa Weber is the former managing editor of CURE and is covering the annual meeting of the American Society of Clinical Oncology.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.
Related Content